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A B S T R A C T
The vitamin D system is deregulated during development and progression of several cancer types. Data
on the expression of the vitamin D system in the diseased pancreas are missing. The aim of this study was
to investigate the expression of the vitamin D receptor (VDR), 1,25-dihydroxyvitamin D3 24-hydroxylase
(CYP24A1), and the calcium-sensing receptor (CaSR), a vitamin D target gene, in the different regions of
the pancreas in patients with chronic pancreatitis (n = 6) and pancreatic ductal adenocarcinomas (PDAC)
(n = 17). We analyzed the expression of these genes at mRNA and protein level with quantitative real-time
RT-PCR and immunostaining. mRNA expression of CYP24A1 and VDR was signiﬁcantly increased in
tumors compared with the adjacent non-tumorous tissue (p < 0.01), while CaSR mRNA expression
decreased. Both the VDR and the CaSR protein were highly expressed in the endocrine compared with the
exocrine pancreas. In CP the CYP24A1 expression was highest in the endocrine pancreas, while in PDACs
in the transformed ducts. In the PDAC patients CYP24A1 expression in the islets was signiﬁcantly lower
than in CP patients. Our data suggest that during ductal adenocarcinoma development the vitamin D
system in the pancreas becomes deregulated on two levels: in the islets CYP24A1 expression decreases
weakening the negative feedback regulation of the vitamin D-dependent insulin synthesis/secretion. In
the transformed ducts CYP24A1 expression increases, impairing the antiproliferative effect of vitamin D
in these cells.
ã 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).
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Diseases of the pancreas represent a large burden both for
patients and for the public health system. Pancreatic cancer has
poor clinical outcome, the 5-year survival rate is less than 6%
(http://www.pancreatic.org2). The management and follow-up of
these patients are still a major challenge for health care providers.
Despite of relatively low incidence, death due to pancreatic cancer
ranks fourth among cancer-related deaths in the Western world
due to the poor survival rate and rapid fatality after diagnosis [1].
Vitamin D is a pluripotent secosteroid hormone, which plays an
important role in a variety of physiologic and pathologic processesAbbreviations: VDR, vitamin D receptor; CYP24A1,1,25-dihydroxyvitamin D3 24-
hydroxylase; CaSR, calcium-sensing receptor; 1,25(OH)2D3, 1,25-dihydroxyvitamin
D3; CYP27B1, 25-hydroxyvitamin D3 1a-hydroxylase; VDRE, vitamin D response
elements; PDAC, pancreatic ductal adenocarcinoma; CP, chronic pancreatitis.
* Corresponding author. Tel.: +43 1 4040051230; fax: +43 1 4040051300.
E-mail address: enikoe.kallay@meduniwien.ac.at (E. Kállay).
1 Contributed equally to this work.
2 Accessed on 21st of August 2014.
http://dx.doi.org/10.1016/j.jsbmb.2014.07.011
0960-0760/ã 2014 The Authors. Published by Elsevier Ltd. This is an open access articof the human body. In addition to its classical calciotropic effects, a
whole spectrum of biological activities of 1,25-dihydroxyvitamin
D3 (1,25(OH)2D3), the active form of vitamin D, have been detected
during the last two decades in different tissues, e.g., breast, colon,
and pancreas [2,3]. These tissues – although not involved in the
systemic regulation of 1,25(OH)2D3 levels – are able to activate and
degrade vitamin D. 25-Hydroxyvitamin D3 1a-hydroxylase
(CYP27B1) hydroxylates the precursor 25-hydroxyvitamin D3 (25
(OH)D3) at position C-1a to form the hormonally active metabolite
1,25(OH)2D3 [4]. Both 25(OH)D3 and 1,25(OH)2D3 are able to bind
to the vitamin D receptor (VDR), which acts as a transcription
factor and binds to the vitamin D response elements (VDRE) in the
promoter of vitamin D target genes [5]. One of the main target
genes of vitamin D bound to the VDR is 1,25-dihydroxyvitamin-D3
24-hydroxylase (CYP24A1). This enzyme catabolizes 25(OH)D3 as
well as 1,25(OH)2D3, resulting in the formation of calcitroic acid or
1a,25-(OH)2D3-26,23-lactone [6]. CYP24A1 is often overexpressed
in cancer [7]. The promoter of the calcium sensing receptor (CaSR)
gene, a G-protein coupled receptor, harbors two VDREs suggesting
that CaSR is a vitamin D target gene [8]. In the pancreas, the CaSR is
involved in regulating insulin secretion [9].le under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
Table 1
Pathological characteristics of the patient cohort used for mRNA analysis.
Pancreatic ductal adenocarcinoma
Number of patients 11
Gender (male/female) 6/5
Age (median, range) 60 (46–71)
Tumor grade (TI/II/III) 0/4/7
TNM classiﬁcation
Primary tumor size (1/2/3/4) 0/1/10/0
Lymph node inﬁltration (N) 10
Distant metastasis (M) (site) 0
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modulate both the endocrine and immune system [2]. Moreover, it
plays a crucial role in regulating cellular processes like cell
proliferation, differentiation, and apoptosis in an autocrine and/or
paracrine manner, therefore, it is not surprising that the vitamin D
system is deregulated in many forms of cancer [7].
The association between single nucleotide polymorphisms in
genes of the vitamin D system and the risk of colorectal, breast, and
prostate cancer has been described previously [10]. In a very recent
study, Anderson et al. were able to link single nucleotide
polymorphisms in vitamin D system genes and CaSR to pancreatic
cancer risk [11].
While Mohr et al. found an inverse association between UV-B
radiation which increases vitamin D production in the skin (the
main source of vitamin D) and pancreatic cancer mortality [12], the
results of studies trying to establish a link between dietary vitamin
D intake and risk of pancreatic cancer are inconclusive. Skinner
et al. [13] reported a reduction of the relative risk of pancreatic
cancer with high vitamin D intake (600 IU/day), while a recent
population-based study observed increased risk of pancreatic
cancer in men with higher dietary vitamin D intake [14]. The
results of cohort studies evaluating the association of circulating
25(OH)D3 levels with pancreatic cancer risk are further inconsis-
tent; two studies by Stolzenberg-Solomon et al. reported an
elevated risk for pancreatic cancer among patients with high 25
(OH)D3 levels [15,16], whereas another study from the same group
found no association [17]. A very recent meta-analysis was unable
to show any correlation between dietary vitamin D or 25(OH)D3
levels and risk of pancreatic cancer [18]. On the other hand, Wolpin
et al. [19] showed that serum 25(OH)D3 levels below 45.6 nmol/L
were associated with higher pancreatic cancer risk. Similarly, Bao
et al. [20] found positive correlation between high predicted 25
(OH)D3 score (predictors based on race, geographic region, vitamin
D intake, body mass index, and physical activity) and lower risk for
development of pancreatic cancer. A retrospective study showed
that vitamin D deﬁciency and insufﬁciency were common among
patients with adenocarcinoma of the pancreas and that there was a
signiﬁcant association between low vitamin D levels and poor
outcome in patients with stage III and IV tumors [21].
The conﬂicting data on the role of circulating 25(OH)D3 in
pancreatic carcinogenesis emphasize the need to study the role of
the vitamin D system in pancreatic malignancies more in depth.
We hypothesized that the expression of the vitamin D system is
deregulated during pancreatic tumorigenesis. Therefore, in the
present study, we evaluated the local expression of key factors of
the vitamin D system and the vitamin D target gene CaSR in
samples from chronic pancreatitis and pancreatic ductal adeno-
carcinoma in the different cell types of the pancreas to get new
insights into the possible role of vitamin D-related pathomechan-
isms. Our results suggest that during the development of ductal
adenocarcinoma the vitamin D system becomes impaired both in
the endocrine and exocrine pancreas, affecting the cross-talk
between these two systems.
2. Materials and methods
2.1. Patients
This study was conducted according to the Declaration of
Helsinki. Written informed consent was obtained from all patients.
Permission from the Ethics Commission of the Semmelweis
University Medical School was granted prior to initiation of the
study (ethical approval number 6626-1/2012/EKU). All consenting
patients during the recruitment period were included in the
analysis. We were able to obtain fresh material only in a subset of
PDAC patients (n = 11). After surgical resection, parts of pancreatictissue were frozen in 80 C for RNA extraction, or formalin-ﬁxed
and parafﬁn embedded. Fresh frozen material was used for qRT-
PCR and formalin-ﬁxed parafﬁn embedded tissue was used for
immunohistochemical and immunoﬂuorescence staining. Demo-
graphic and pathological characteristics of patients who under-
went pancreatoduodenectomy are shown in Tables 1 and 2 .
Malignant tumors were diagnosed as pancreatic ductal adenocar-
cinoma (PDAC) according to the World Health Organization (WHO)
classiﬁcation [22].
2.2. RNA extraction, reverse transcription (RT), and quantitative real
time RT-PCR
Total RNA from fresh frozen samples was isolated with TRIzol
reagent (Invitrogen, Grand Island, NY, USA) according to the
manufacturer's instructions. 2 mg of total RNA was reverse
transcribed using RevertAid H Minus Reverse Transcriptase and
Random Hexamer Primers (Fermentas, Ontario, Canada). Quanti-
tative real time RT-PCR (qRT-PCR) was performed as described
before [23]. We normalized relative expression of the target genes
to the expression of two housekeeping genes suggested in the
literature [24]: glutaminyl-tRNA synthetase (QARS), and polymer-
ase (RNA) II (DNA directed) polypeptide (POL2RL). Expression
levels were set relative to the calibrator (cDNA converted from total
human RNA obtained from Clontech, Mountain View, CA, USA) and
calculated according to the DDCT method. Primer sequences used
were as follows: QARS (Fwd: GAGCGACTATTCCAGCAC, Rev:
ATGCCAGGTTCAGGTCAC), POL2RL (Fwd: ACCGAGGGG-
GATGCGCTGGAT, Rev: CAGCGTGGTCACTTCTC, and VDR (Fwd:
CGTCCAGCTTCTCCAATCTG, Rev: GTGAGGTCTCTGAATCCTGGT)
were used. Primer sequences for CYP24A1 [25], and the CaSR
[26] have been published previously.
2.3. Immunohistochemistry
Immunohistochemistry for CYP24A1, VDR, and Ki67 was
performed with a two-step indirect immunoperoxidase technique
on 5 mm sections of formalin ﬁxed parafﬁn-embedded tissue
samples as described before [25]; VDR (dilution 1:100; Sigma–
Aldrich, St. Louis, USA), Ki67 (dilution 1:100; Dako, Glostrup,
Denmark). For immunohistochemical visualization of CaSR,
samples were deparafﬁnized with xylol, rehydrated in ethanol
and washed in phosphate buffered saline (PBS, pH 7.2), followed by
antigen retrieval in EB-DEPP-9 buffer (1:20 in deionized water,
Eubio, Vienna, Austria) for 10 min. Sections were then washed in
PBS before permeabilization with 0.2% Tween-20 for 15 minutes
and blocked in 5% fetal bovine serum in PBS. The samples were
incubated with the primary antibody (monoclonal anti-mouse
CaSR, 1:300, Abcam, Cambridge, UK) for one hour at room
temperature. After a series of wash steps in PBS, staining was
detected using the dextran polymer peroxidase Envision system
(Dako, Glostrup, Denmark). The sections were washed, counter-
stained with Hematoxylin (Dako) and mounted as described before
Table 2
Pathological characteristics of the patient cohort used for protien analysis.
Chronic pancreatitis Pancreatic ductal adenocarcinoma
Number of patients 6 17
Gender (male/female) 4/2 6/11
Age (median, range) 67 (32–74) 59 (46–74)
Tumor grade (TI/II/III) 1/8/8
TNM classiﬁcation
Primary tumor size (1/2/3/4) 0/3/12/2
Lymph node inﬁltration (N) 11
Distant metastasis (M) (site) 1 (liver)
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negative control, the primary antibody was replaced with an
isotype speciﬁc IgG.
2.4. Immunoﬂuorescence staining
5 mm slides of formalin ﬁxed parafﬁn embedded tissue
(adenocarcinoma and chronic pancreatitis) were deparafﬁnized
with xylol and rehydrated in ethanol. Antigen retrieval was
performed in 0.05% citrate buffer, followed by wash steps in PBS.
Samples were then permeabilized in 0.2% Tween, blocked in 5%
goat serum and co-incubated with VDR antibody (1:100, Sigma–
Aldrich) and synaptophysin antibody (1:100, Biogenex, Fremont,
CA, USA) or VDR antibody and CaSR antibody (1:200, Abcam).
After washing, samples were incubated with Dylight 549 goat-
anti-rabbit IgG (1:500, Vector Laboratories, Burlingame, CA, USA)
and Alexaﬂuor 647 goat-anti-mouse IgG (1:1000, Jackson
ImmunoResearch, Suffolk, UK). Nuclei were stained with 40,6-
diamidino-2-phenylindole (DAPI, Roche, Basel, Switzerland) and
mounted with Fluoromount-G (Southern Biotech, Birmingham,
AL, USA).
2.5. Automated analysis of stained sections
Images of whole tissue sections were acquired using Tissue-
FAXS (TissueGnostics GmbH, Vienna, Austria) [27]. We analyzed
the number of positive cells using the HistoQuest software
(TissueGnostics GmbH). This software allows automated acquisi-
tion of both immunoﬂuorescence and immunohistochemistry
images. After selection of the regions of interest (acinar, ductal,
stromal, endocrine, and tumor cells) by a pathologist, quantitative
analysis of the percentage of positive staining was carried out
using HistoQuest. We analyzed 5000 cells per slide for each cell
type (acinar, endocrine, stromal, tumor and ductal). The mean area
of each investigated region was 3.4 mm2. Fluorophores used for
immunoﬂuorescence were: DAPI (for nucleus), TxRed (for VDR),
and Cy5 (for CaSR and synaptophysin). Using extended focus, a
feature of this software, we were able to ensure correct focus by
merging several z-stacks into one sharp image. Images were
acquired at exposure times where IgG controls were completely
negative to ensure that unspeciﬁc staining was gated out.
2.6. Statistical analysis
We used SPSS statistics package, v18.0 for statistical analysis
and GraphPadPrism v5.0 for designing graphs. We performed
paired t-tests on log2-transformed, normally distributed data for
mRNA expression. An outliers test was performed using GraphPad
QuickCalcs and outliers were excluded from analysis. We used
Wilcoxon signed ranks test for analyzing protein expression in
patients with CP or PDAC, and the Mann–Whitney U-test tocompare between disease groups. These tests were corrected for
multiple comparisons using a Bonferroni–Holm correction. P-
values <0.05 were considered signiﬁcant. Correlation analysis was
performed by calculation of Spearman's correlation coefﬁcient (r)
with two-tailed signiﬁcance levels.
3. Results
3.1. mRNA expression of VDR, CYP24A1, and CaSR in pancreatic ductal
adenocarcinoma (PDAC)
In our patient cohort (Table 1), we observed a signiﬁcant
upregulation of VDR (mean 3.7-fold) as well as of CYP24A1 (mean
30.78-fold) mRNA expression in PDAC compared with adjacent
parts of the pancreas. mRNA expression of the CaSR decreased in
the tumors of most patients by 50%, however did not reach
statistical signiﬁcance (Fig. 1A). CYP27B1 levels did not change
(data not shown). Our data are consistent with the microarray gene
expression data published in the GEO database by Zhang et al. [28]
(Fig. 1B), suggesting that our patient cohort was representative,
despite the low sample size.
3.2. Protein expression and localization of the VDR in patients with
chronic pancreatitis (CP) and pancreatic ductal adenocarcinoma
(PDAC)
In our patient cohort (Table 2) we analyzed expression and
localization of the VDR in different regions of the pancreatic tissue.
Expression of VDR was signiﬁcantly higher in the endocrine islets
compared with all other regions of the pancreas in patients with CP
as well as in patients with PDAC. In PDAC patients, VDR expression
was signiﬁcantly higher also in acinar and ductal cells compared
with the stroma (Fig. 2).
3.3. Protein expression and localization of CYP24A1 in patients with
chronic pancreatitis (CP) and pancreatic ductal adenocarcinoma
(PDAC)
We analyzed expression of CYP24A1 in different regions of the
pancreatic tissue (Fig. 3A). In CP patients, CYP24A1 expression
varied signiﬁcantly among the different regions of the pancreas,
increasing in the following order: stroma < acinar cells < ducts <
endocrine islets. In PDAC patients, the tumor expressed signiﬁ-
cantly more CYP24A1 than the acini, endocrine islets, or stroma
(Fig. 3B). The endocrine islets of PDAC patients expressed
signiﬁcantly less CYP24A1 than the islets of CP patients (Fig. 3B).
CYP24A1 is a VDR target gene; therefore we tested whether
CYP24A1 expression correlates with VDR expression. Spearman's
correlation analysis showed that CYP24A1 and VDR correlated
strongly in CP patients; however, this correlation was lost in PDAC
patients (Table 3).
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Fig. 1. mRNA expression of the VDR and CYP24A1 is signiﬁcantly increased and CaSR expression decreases in PDAC compared with adjacent non-tumorous (NT) parts of the
pancreas. (A) mRNA expression (n = 11) was assessed by qRT-PCR and set relative to calibrator. (B) Data originate from a microarray analysis of mRNA from patients suffering
from PDAC [28]. Median, interquartile range and whiskers according to Tukey are shown. Statistics were calculated using paired t-test on log2-transformed data. Among the
values for CYP24A1 expression we identiﬁed one outlier in each dataset. (**p < 0.01, ***p < 0.001).
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(CP) and pancreatic ductal adenocarcinoma (PDAC)
We analyzed expression and intensity of the proliferation
marker, Ki67 in different regions of the pancreatic tissue. In PDAC
samples, Ki67 expression was much stronger in the tumor
compared with the other regions of the tissue (Fig. 4). In CP
patients Ki67 staining was very weak in all regions analyzed.
Spearman's correlation analysis showed signiﬁcant correlation
between CYP24A1 and Ki67 in the tumor and stroma of the PDACFig. 2. Protein expression of VDR in CP and PDAC. VDR is highly expressed in endocrine
region of chronic pancreatitis is shown. Black bar equals 50 mm. (B) Protein expressio
interquartile range and whiskers according to Tukey are shown. Wilcoxon signed ranks 
Mann–Whitney U-test to compare between disease groups. Both tests were followed by B
statistically signiﬁcant difference from stroma (*p < 0.05).patients. In CP patients CYP24A1 and Ki67 expression did not
correlate (Table 4).
3.5. Protein expression and localization of the calcium-sensing
receptor (CaSR) in patients with (CP) and pancreatic ductal
adenocarcinoma (PDAC)
Expression of the vitamin D target gene, CaSR, was strongest in
the endocrine islets in all samples. CaSR protein was expressed also
in the acinar and duct cells, however at much lower level (Fig. 5). islets compared with other parts of the pancreas. (A) IHC of an endocrine islet in a
n was determined using IHC, percentage of VDR positive cells is shown. Median,
test was applied to compare protein expression in patients with CP and PDAC, and
onferroni–Holm correction for multiple comparisons. Asterisks above boxes indicate
Fig. 3. Expression of CYP24A1 in pancreatic ductal adenocarcinoma compared with non-tumorous regions of the same patient. (A) IHC of CYP24A1 in a patient with PDAC is
shown. Black bar equals 50 mM. (B) Protein expression of the CYP24A1 is increased in ductal adenocarcinoma compared with other regions of pancreatic tissue. Protein
expression was determined using IHC, percentage of CYP24A1 positive cells is shown. Median, interquartile range and whiskers according to Tukey are shown. Wilcoxon
signed ranks test was applied to compare protein expression in patients with CP and PDAC, and Mann–Whitney U-test to compare between disease groups. Both tests were
followed by Bonferroni–Holm correction for multiple comparisons. Asterisks above boxes indicate statistically signiﬁcant difference from stroma (*p < 0.05). Hashtags
indicate statistically signiﬁcant difference between patients with CP and PDAC (#p < 0.05, ##p < 0.01). (For interpretation of the references to color in this ﬁgure legend, the
reader is referred to the web version of this article.)
Table 3
VDR expression correlates with CYP24A1 expression in CP but not in PDAC patients.
VDR
CP PDAC
CYP24A1 Correlation coefﬁcient 0.715 0.206
p-value <0.001 Not signiﬁcant
Table 4
Ki67 expression correlates with CYP24A1 expression in PDAC but not in CP patients.
Ki67
CP PDAC
CYP24A1 Correlation coefﬁcient 0.377 0.409
p-value Not signiﬁcant <0.01
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non-tumorous and cancerous tissue, consistent with previous
ﬁndings [29].
3.6. Co-expression of VDR and CaSR protein in endocrine cells
In order to assess whether the VDR and CaSR were expressed in
the same cells of the endocrine islets, we performed dual
immunoﬂuorescence staining. We stained VDR/synaptophysin
and CaSR/VDR in combination and were able to show that VDR
co-localizes with synaptophysin (Fig. 6A) and is expressed in theFig. 4. Expression of Ki67 in chronic pancreatitis and pancreatic ductal adenocarcinoma
Ki67 expression is increased in tumor compared with non-tumorous regions of the same 
shown. (For interpretation of the references to color in this ﬁgure legend, the reader issame cells as the CaSR (Fig. 6B), implying a co-expression of CaSR
with synaptophysin. Thus, we show that the cells expressing the
VDR and the CaSR are the synaptophysin expressing endocrine
cells of the islets.
4. Discussion
In this study, we investigated the expression of VDR, CYP24A1
and the vitamin D target gene CaSR in diseased pancreatic tissue.
We show for the ﬁrst time that the expression of the vitamin D
degrading enzyme, CYP24A1 is increased both during. CP patients have low expression of the proliferative marker Ki67. In PDAC patients
patient. Immunostaining of Ki67 (brown) in patient with CP (left) and PDAC (right) is
 referred to the web version of this article.)
Fig. 5. CaSR expression is high in endocrine islets compared with other parts of the
pancreas. IHC of an endocrine islet with surrounding acinar and duct cells is shown.
Black bar equals 50 mm.
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transformation (as in pancreatic ductal adenocarcinoma). In all
regions of the pancreas CYP24A1 expression is generally higher in
CP patients than in PDAC patients. By comparing expression of the
studied proteins in the various cell types of the pancreas, we are
the ﬁrst to show that during ductal adenocarcinoma development,
the islet cells lose CYP24A1 expression while the transformed
ductal cells up-regulate CYP24A1 expression.
The pancreas is a very complex organ, consisting of an
endocrine and exocrine part. Therefore, we examined the
expression pattern of the two of most-relevant genes for vitamin
D metabolism and signaling (VDR and CYP24A1) and also included
one vitamin D target gene (CaSR) in the different morphological
structures of the pancreas, such as acinar cells, ducts, endocrine
cells, and stroma as well as tumor regions from patients with PDAC.
mRNA levels of the vitamin D activating enzyme, 25-hydroxyvi-
tamin D3-1-alpha hydroxylase (CYP27B1) was unchanged in our
patient cohort (data not shown).Fig. 6. VDR and the CaSR are expressed in the endocrine cells of the pancreas. (A) Immun
VDR (red) and the merged picture. (B) Immunoﬂuorescence staining of the CaSR (whitIn CP patients, we found highest CYP24A1 levels in the
endocrine cells. Interestingly, in PDAC patients, the tumor cells
expressed more CYP24A1 than any other cell type, even more than
the endocrine cells. It seems that during malignant transformation,
the untransformed endocrine cells lose their CYP24A1 expression,
while the transformed ductal cells accumulate CYP24A1. Whether
this is causally linked with the transformation process or it is a
consequence of this process, needs to be determined.
The vitamin D degrading enzyme CYP24A1 is the main target
gene of the hormonally active form of vitamin D, 1,25(OH)2D3 and
is most abundant in the kidney, but it is also expressed in several
other tissues [30–33]. The expression of CYP24A1 is increased in
several malignancies, such as colon, ovary, breast, lung, and
esophageal tumors [34–37]. This overexpression probably leads to
an immediate degradation of the locally available 1,25(OH)2D3,
impairing its antitumorigenic action in the tumor tissue. CYP24A1
gene transcription is initiated upon binding of the VDR/1,25
(OH)2D3-complex to the VDREs in the gene promoter. The
simultaneous up-regulation of CYP24A1 and VDR mRNA in PDAC
could lead to the assumption of a VDR-dependent CYP24A1 mRNA
enhancement. This seems to be the case in CP patients, where
CYP24A1 expression correlates with VDR signiﬁcantly. However,
this correlation is lost in PDAC patients where VDR protein levels
are highest in the endocrine cells while the CYP24A1 is highest in
tumor cells.
From these data we speculate that up-regulation of CYP24A1 in
the tumor is uncoupled from VDR, and therefore is independent of
the local levels of 1,25(OH)2D3, as it has been suggested for benign
and malignant tumors of the colon [25]. The high CYP24A1 levels
would degrade the locally available 1,25(OH)2D3, preventing its
antitumorigenic action. One reason leading to CYP24A1 over-
expression in pancreatic tumors could be an activating mutation of
K-ras. K-ras mutations occur in almost all advanced PDAC cases
[38,39]. Zhang et al. have shown that lung cancer cell lines
harboring a K-ras mutation express high CYP24A1 levels, while
VDR expression is low [40]. Anderson et al. have shown recentlyoﬂuorescence staining of the endocrine marker synaptophysin (SYN, green) and the
e) and the VDR (red) and the merged picture. White bar equals 50 mM.
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risk of pancreatic cancer [11]. Whether this particular modiﬁcation
has any effect on the activity or expression of CYP24A1 is not
known.
We found the highest expression of VDR and CaSR in the
endocrine cells of the pancreas while the exocrine pancreas
expressed much lower levels. The up-regulation of VDR in
pancreatic cancer cells compared with normal cells has been
shown in vitro in primary tumor cells, supporting our present
results on mRNA level [41]. Pancreatic cancer cells responded to
treatment with an 1,25(OH)2D3 analogue by inhibition of
proliferation [42,43]. Whether up-regulation of the VDR in
pancreatic cancer can be seen as a defense mechanism to make
use of the locally available 1,25(OH)2D3more efﬁciently remains to
be investigated. Interestingly, single nucleotide polymorphisms in
the VDR gene are associated with a higher risk for pancreatic cancer
[11,44]. These results emphasize the possible impact of the vitamin
D receptor in malignant transformation of the pancreas.
In our samples, VDR protein is expressed much higher in the
endocrine islets compared with all other regions in CP as well as in
PDAC samples. These results suggest that VDR, and consequently
vitamin D, play a pivotal role in the endocrine function of the
pancreas; however, it might be less important in exocrine
secretion.
It has been shown previously that mice lacking the VDR have
impaired insulin secretion [45]. The role of vitamin D and
involvement of the VDR in the pathogenesis of insulin-dependent
diabetes mellitus (diabetes type 1) has been studied extensively
[46]. A link between type 1 diabetes and VDR in the b-cells of the
endocrine islets has been suggested previously [47,48]. Wolden-
Kirk et al. showed recently that 1,25(OH)2D3 protects b-cells from
cytokine induced apoptosis and impaired insulin secretion [49].
Moreover, the promoter of the human insulin gene harbors a VDRE
[50]. It seems that 1,25(OH)2D3 increases both synthesis and
secretion of insulin [51] therefore 1,25(OH)2D3 levels in the
endocrine cells are tightly regulated by CYP24A1. At the same time,
insulin promotes pancreatic cancer in both epidemiologic and
animal studies either directly or indirectly [52,53].
In the endocrine cells of PDAC patients, CYP24A1 expression
was signiﬁcantly lower than in the patients with CP (and probably
in the normal pancreas), while it was increased in the tumor cells.
We speculate that the tight regulation of 1,25(OH)2D3 levels,
needed in these cells for a balanced vitamin D-dependent
regulation of insulin secretion is lost. As a consequence, higher
vitamin D levels in patients with low CYP24A1 levels in the
endocrine cells would lead to enhanced insulin secretion. This
could then promote growth of neighboring tumor cells in a
paracrine manner. Additionally, in the tumor itself, the high
CYP24A1 levels would catabolize 1,25(OH)2D3 immediately,
impairing its anti-tumorigenic effects. Indeed, in PDAC patients
CYP24A1 levels correlated signiﬁcantly with Ki67 expression,
suggesting that tumors overexpressing CYP24A1 are highly
proliferative. This hypothesis might explain the positive associa-
tions observed in some studies between vitamin D and pancreatic
cancer, however it needs further proof.
It seems that vitamin D and calcium could co-regulate
production of insulin. Faure-Dussert et al., in a study using vitamin
D-deﬁcient rat islets, demonstrated increased b-cell sensitivity to
1,25(OH)2D3-dependent insulin secretion under hypocalcemic
conditions [54]. Furthermore, Squires et al. have shown that the
CaSR negatively modulates secretion of insulin in the pancreas [9].
In our patients we show co-expression of VDR and CaSR in the
endocrine islets leading us to speculate a cross talk between these
molecules in the pancreatic islets.
The main limitations of this descriptive pilot study are the small
patient number and the lack of normal tissue. Its strength is thatwe examined the expression of the vitamin D system in the
different cell types of the pancreas and found a cell type-
dependent deregulation of the vitamin D pathway in ductal
adenocarcinoma development.
5. Conclusions
In this study, we show for the ﬁrst time that CYP24A1 is
overexpressed in pancreatic tumors on mRNA as well as on protein
level. In chronic pancreatitis patients the signiﬁcant correlation of
CYP24A1 and VDR suggests that high CYP24A1 expression in the
islets is a physiological up-regulation of CYP24A1. This correlation
is lost during malignant transformation. Further, our data suggest
that during ductal adenocarcinoma development the vitamin D
system in the pancreas becomes deregulated on two levels: In the
islets CYP24A1 expression decreases weakening the negative
feedback regulation of the vitamin D-dependent insulin synthesis
and secretion. The higher insulin levels could promote tumor
growth. In the transformed ducts CYP24A1 expression increases,
impairing the antiproliferative effect of vitamin D in these cells.
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